MANAGEMENT OF GLAUCOMA: EFFECTIVE DRUG DELIVERY VIA NIOSOMES
Glaucoma is a term used for a group of diseases; associated with optic nerve damage which leads to loss of retinal ganglionic cells. The changes stimulated in the optic nerve head cause visual field restriction which may ultimately result in blindness. Conventionally, the drugs used in treatment are ocular anti-hypertensives and are available as eye drops. Challenges faced in ocular delivery of a drug reduce the efficacy of such formulations. In a disease like glaucoma which is a leading cause of irreversible blindness, effective delivery of drug to the site of absorption is paramount in order to prevent disease progression. The novel drug delivery systems have shown great promise in this regard. They have been developed with a viewpoint to improve ocular retention of therapeutic agents. Niosomes have been exploited well and have elicited a positive response. The review is aimed at bringing out facts about the disease including worldwide prevalence, types, treatment, its impact and also constraints in ocular drug delivery, drug delivery alternatives, and niosomes in particular with their composition, advantages and their potential in management of ocular hypertension.
2. Saxena R, Singh D, Vashisht P, Glaucoma: An emerging peril. Indian J Community Med, 2013, 38(3), 135-137.
3. Kaur I P, Garg A, Singla A K, Aggarwal D. Vesicular systems in ocular drug delivery: an overview, I J Pharm, 2004, 209, 1-14.
4. Sahoo R K, Biswas N, Guha A, Sahoo N and Kuotso K, Nonionic surfactant vesicles in ocular delivery: Innovative approaches and perspectives, BioMed Res. Int., Hindawi Publishing Corporation, Vol. 2014, 1-12.
5. Kazi KM, Mandal AS, Biswas N, Guha A, Chatterjee S, Behera M et al., Niosome: A future of targeted drug delivery systems, J Adv Pharm Technol Res., 2010, 1(4), 374â€“380.
6. Tham Y C, Li X, Wong T Y, Quigley A H, Aung T, Cheng C Y, Global prevalence of glaucoma and projections of glaucoma burden through 2040 A systematic review and meta-analysis, Ophthalmology, 2014, 121(11), 2081-2090.
7. Giangiacomo A, Coleman AL. The epidemiology of glaucoma, Glaucoma, Springer Berlin Heidelberg, 2009, Pg 13-21.
8. Quigley H A, Broman A T, The number of people with glaucoma worldwide in 2010 and 2020, Br J of Ophthalmol., 2006, 90, 262-267.
9. Dandona L , Dandona R, Srinivas M, Mandal P, John RK, McCarty CA, Rao GN, Open angle glaucoma in an urban population in southern India: the Andhra Pradesh eye disease study, Ophthalmology, 2000, 107(9), 1702-9.
10. Ramakrishnan R, Nirmalan PK, Krishnadas R, Thulasiraj RD, Tielsch JM, Katz J, Friedman DS, Robin AL, Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey, Ophthalmology, 2003, 110(8), 1484-90.
11. Vijaya L , George R, Paul PG, Baskaran M, Arvind H, Raju P, Ramesh SV, Kumaramanickavel G, McCarty C, Prevalence of open angle glaucoma in a rural south Indian population, Invest Ophthalmol Vis Sci., 2005, 46(12), 4461-7.
12. Moore DB, Glaucoma in the developing world, Available from: www.eyewiki.aao.org.
13. Patient Guide, The Glaucoma Foundation, Available from: https://www.glaucomafoundation.org/docs/PatientGuide.pdf
14. Medication Guide, Glaucoma Research Foundation, Available from: www.glaucoma.org.
15. Quigley AH, Number of People with Glaucoma Worldwide, Br J Ophthalmol., 1996, 80, 389-393.
16. Leske MC, Connell AM, Schachat AP, Hyman L, The Barbados eye study, Prevalence of open angle glaucoma, Arch Ophthalmol., 1994, 112(6), 821-9.
17. Leske MC, Connell AM, Wu SY, Nemesure B, Li X, Schachat A, Hennis A, Incidence of open-angle glaucoma: the Barbados eye studies, The Barbados eye studies group, Arch Ophthalmol., 2001, 119(1), 89-95.
18. Cho HK, Kee C, Population-based glaucoma prevalence studies in Asians, Surv Ophthalmol., 2014, 59(4), 434-47.
19. Traverso CE, Walt JG, Kelly SP, Hommer AH, Bron AM, Denis P et al., Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe, Br J Ophthalmol., 2005, 89, 1245-1249.
20. Thyleforl B, Negrel A.D, The global impact of glaucoma, Bulletin of the World Health Organization, 1994, 72(3), 323-326.
21. Varma R, Lee PP, Goldberg I, Kotak S, An Assessment of the Health and Economic Burdens of Glaucoma, Am J Ophthalmol., 2011, 152(4), 515-522.
22. Covin YN, Laroche D, The societal costs of blindness from uncontrolled glaucoma, Glaucoma Today, 2014, Jul-Aug, 28-29.
23. Kumari A, Sharma PK, Garg VK, Garg G, Ocular inserts-Advancement in therapy of eye diseases, J Adv Pharm Technol Res., 2010, 1(3), 291-296.
24. Patel A, Cholkar K, Agrahari V, Mitra AK, Ocular drug delivery systems: An overview, World J Pharmacol., 2013, 2(2), 47-64
25. Xu Q, Kambhampati SP, Kannan RM, Nanotechnology approaches for ocular drug delivery, Middle East Afr J Ophthalmol., 2013, 20(1), 26-37.
26. Kumar GP, Rajeshwarrao P, Nonionic surfactant vesicular systems for effective drug delivery-an overview, Acta Pharmaceutica Sinica B, 2011, 1(4), 208-219.
27. Sankhyan A, Pawar P, Recent trends in niosome as vesicular drug delivery system, J. Appl. Pharm. Sci., 2012, 2(06), 20-32.
28. Mujoriya RZ, Dhamande K, Dr. Bodla R B, Niosomal drug delivery system- A Review, Int. J. Appl. Pharm., 2011, 3(3), 7-10.
29. Dahiya N K, Rao R, Nanda S, Preparation and characterization techniques in niosomal vesicular systems-A Review, J. Pharm. Biomed. Sci., 2011, 5(20), 1-8.
30. Singh S, Niosomes: A role in targeted drug delivery systems, Int. J. Pharm. Sci. Res., 2013, 4(2), 550-557.
31. Arora V, Rastogi S, Siddiqui AW, Gupta M, Bhalla V, Pharmaceutical applications of nano-niosomes in drug, vaccine and gene delivery, Int. J. Pharm. Sci. Nanotechnol., 2014, 7(4), 2603-2611.
32. Kaur I P, Smitha R, Aggarwal D, Kapil M, Acetazolamide: future perspective in topical glaucoma therapeutics, Int. J. Pharm., 2002, 248, 1-14.
33. Aggarwal D, Garg A, Kaur I P, Development of a topical niosomal preparation of acetazolamide: preparation and evaluation, J Pharm. Pharmcol., 2004, 56, 1509-1517.
34. Kaur I P, Mitra A K, Aggarwal D, Development of a vesicular system for effective ocular delivery of acetazolamide A comprehensive approach and successful venture, J. Drug Del. Sci. Tech., 2007, 17(1), 33-41.
35. Guinedi A S, Mortada N D, Mansour S, Hathout R M, Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide, Int. J Pharm., 2005, 306, 71-82.
36. El-Menshawe S F, A novel approach to topical acetazolamide/PEG 400 ocular niosomes, J. Drug Del. Sci. Tech., 2012, 22(4), 295-299.
37. Aggarwal D, Kaur I P, Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system, Int. J. Pharm., 2005, 290, 155-159.
38. Kaur I P, Aggarwal D, Singh H, Kakkar S, Improved ocular absorption kinetics of timolol maletae loaded into a bioadhesive niosomal delivery system, Graefeâ€™s Arch. Clin. Exp. Ophthalmol., 2010, 248, 1467-1472.
39. Prabhu P, Nitish R K, Koland M, Harish NM, Vijayanarayan K, Dhondge G, Charyulu N, Preparation and evaluation of nano-vesicles of brimonidine tartrate as an ocular drug delivery system, J Young Pharm., 2010, 2(4), 356-361.
40. Maiti S, Paul S, Mondol R, Ray S, Sa B, Nanovesicular formulation of brimonidine tartrate for the management of glaucoma: In vitro and in vivo evaluation, AAPS PharmSciTech., 2011, 12, 755-763.
41. Satyavathi V, Hasansathali, Ilavarasan R, Sangeetha T, Formulation and evaluation of niosomal in situ gel ocular delivery system of brimonidine tartrate, International Journal of Life Science and Pharma Research, 2012, 2(1), 82-95.
42. Hashim AII, El-dahan MS, Yusif RM, Abd-ElGawad AH, Arima H, Potential use of niosomal hydrogel as an ocular delivery system for atenolol, Biol. Pharm. Bull., 2014, 37(4), 541-551.
43. Dubey A, Prabhu P, Development and investigation of niosomes of brimonidine tartrate and timolol maleate for the treatment of glaucoma, Int. J. PharmTech Res., 2014, 6(3), 942-950.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).